Prevalence and Incidence Studies
Estimating ME/CFS prevalence is complicated by the absence of a diagnostic biomarker, the use of multiple case definitions of varying stringency, and the high rate of undiagnosed cases. Prevalence estimates vary by an order of magnitude depending on methodology and criteria applied.
1 Population-Based Estimates
The most cited prevalence estimates range from 0.1% to 0.9% of the general adult population:
- Fukuda (1994) criteria: Broader definition; population-based studies using these criteria report prevalence of 0.2–0.4% (approximately 800,000–1,600,000 adults in the US)
- Canadian Consensus Criteria (2003): Stricter definition requiring PEM; prevalence approximately 0.1–0.2%
- Institute of Medicine (2015): Estimated 836,000–2,500,000 Americans affected, with 84–91% undiagnosed
- Community surveillance studies: Jason et al. (1999) conducted door-to-door screening in Chicago, identifying a prevalence of 0.42% using the Fukuda criteria—substantially higher than clinic-based estimates, confirming widespread underdiagnosis
2 Geographic and Demographic Variation
Prevalence varies across populations, though much variation may reflect diagnostic practices rather than true disease frequency:
- Sex ratio: Females outnumber males approximately 3–4:1 across most studies (Jason and Mirin 2018) (Lim et al. 2020). This ratio is consistent across cultures and diagnostic criteria, suggesting a biological basis (hormonal, immune, or genetic)
- Age distribution: Earlier studies reported peak onset in the 30–49 age range, though ME/CFS occurs at all ages including children and adolescents. Pediatric prevalence is estimated at 0.1–0.5% (Lim et al. 2020). Recent evidence reveals that this apparently broad peak conceals a bimodal onset-age distribution with two peaks at approximately age 16 and age 37, confirmed across ten European countries (\(n = 9{,}380\)) and replicated in the DecodeME dataset (\(n = 6{,}455\)) (McGrath et al. 2026) (Bakken et al. 2014) (see Section bimodal onset age)
- Ethnic and socioeconomic factors: Community-based studies (as opposed to clinic-based) show similar or higher prevalence in minority and lower-income populations (Jason and Mirin 2018), contradicting the outdated characterization of ME/CFS as a disease of affluent white women. Underdiagnosis in minority populations likely reflects healthcare access disparities rather than lower disease incidence
3 Post-COVID Surge
The COVID-19 pandemic has significantly increased ME/CFS incidence. An estimated 51% of long COVID patients meeting PEM criteria satisfy ME/CFS diagnostic criteria (Komaroff and Lipkin 2023). Given the hundreds of millions of SARS-CoV-2 infections worldwide, the projected increase in ME/CFS prevalence is substantial—potentially doubling or tripling the pre-pandemic patient population. This surge has accelerated research funding and clinical attention but has also strained the already limited specialist infrastructure. Population-level cognitive impact. Beyond prevalence, the post-COVID surge carries significant cognitive morbidity. Hampshire et al. (Hampshire et al. 2024) assessed 112,964 participants from the UK REACT study and documented a graded dose–response relationship between COVID-19 severity and cognitive decline: mild resolved cases showed deficits equivalent to \(\sim\) 3 IQ points, persistent symptoms (Long COVID) \(\sim\) 6 IQ points, and ICU admission \(\sim\) 9 IQ points, with reinfection adding \(\sim\) 2 points per episode. Douaud et al. (Douaud et al. 2022) demonstrated the structural neuroimaging correlate in UK Biobank longitudinal data (\(n = 785\)): grey matter loss in orbitofrontal and parahippocampal regions even after predominantly mild (96% non-hospitalized) infection. At population scale, even the modest 3-point deficit from mild COVID, applied across hundreds of millions of infections, represents a substantial shift in the cognitive capacity distribution—a public health dimension that extends well beyond the ME/CFS patient population but is particularly relevant to understanding the cognitive burden in post-COVID ME/CFS cases (see Chapter Neurological and Neurocognitive Dysfunction, Section Memory Triage Consequence). Vaccination as Prevention Strategy in Children and Adolescents